Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)-Reference-Cited by-同舟云学术

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)

Published:2021-08 Issue:4 Volume:4 Page:543-552
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Morris Michael J.,Mota Jose Mauricio^ORCID,Lacuna Kristine,Hilden Patrick,Gleave Martin,Carducci Michael A.,Saad Fred,Cohn Erica D.,Filipenko Julie,Heller Glenn,Shore Neal,Armstrong Andrew J.,Scher Howard I.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference30 articles.

1. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999

2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

3. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial;Carrie;Lancet Oncol,2016

4. Radiation with or without antiandrogen therapy in recurrent prostate cancer;Shipley;N Engl J Med,2017

5. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy;Zhou;J Clin Oncol,2005

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment;Prostate Cancer and Prostatic Diseases;2024-09-13

2. Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis;Prostate Cancer and Prostatic Diseases;2024-09-13

3. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19);Journal of Clinical Oncology;2024-04-01

4. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy;Journal of Urology;2024-04

5. Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients;Current Opinion in Oncology;2024-02-23